Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn’s?
TOPLINE:Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn's disease....
Anthony Antes
TOPLINE:Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn's disease....
